2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): Clinical Case with Unique Confirmatory Testing

Overview of attention for article published in Journal of Medical Toxicology, July 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy: 1 policy source
twitter: 2 X users

patent: 2 patents

Citations

dimensions_citation: 84 Dimensions

Readers on

mendeley: 63 Mendeley

Summary Policy documents X Patents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

EMCDDA–Europol Joint Report on a new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe)

Cited by European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on 01 Jan 2014

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the leading authority on illicit drugs in the European Union.